Objective: From November 2015 in Korea, the cost for blood glucose test strips (BGTS) for type 2 diabetic (T2D) patients under insulin treatment has been supported by Health Insurance Review and Assessment (HIRA) service. We investigated whether there was improvement of HbA1c in beneficiaries of this policy. Methods: We selected T2D patients with ≥ 180 days’ of the prescription for BGTS (N = 285), and compared their HbA1c level before and after 6 months from the first prescription for BGTS (baseline). We excluded the subjects with duration of insulin treatment < 12 months, any changes in anti-hyperglycemic agents, or with history of malignancy or systemic steroid treatment. Improvement of HbA1c was defined as absolute reduction of HbA1c ≥ 0.6% or HbA1c level at follow-up ≤ 7%. Results: Among study subjects (N = 178; mean age, 68 ± 11 years; mean duration of diabetes, 22 ± 9 years), 82.6% had taken insulin for ≥ 5 years. Mean HbA1c level at the baseline was 8.1 ± 1.2 %, and mean changes in HbA1c level during follow-up was -0.23 ± 0.08 % (P from paired T test = 0.006). Subjects with baseline HbA1c > 9% (P < 0.001), duration of diabetes > 20 years (P = 0.010) and medical care system (P = 0.009) showed a significantly larger decrease in HbA1c level. However, age, gender, fasting c-peptide levels, insulin dose or presence of hypoglycemia at the baseline did not affect the change of HbA1c level. Among subjects with HbA1c >7% at the baseline, the prevalence of improvement of HbA1c was 36.3% and 75.0% in subjects with medical insurance and medical care system, respectively (P = 0.027). Conclusion: BGTS-support by HIRA made a significant improvement of HbA1c in T2D subjects with insulin, which was more prominent in subject with poor glucose control at the baseline or subjects in medical care system.